CA2489057A1 - Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100 - Google Patents

Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100 Download PDF

Info

Publication number
CA2489057A1
CA2489057A1 CA002489057A CA2489057A CA2489057A1 CA 2489057 A1 CA2489057 A1 CA 2489057A1 CA 002489057 A CA002489057 A CA 002489057A CA 2489057 A CA2489057 A CA 2489057A CA 2489057 A1 CA2489057 A1 CA 2489057A1
Authority
CA
Canada
Prior art keywords
apo
antibody
sample
antibodies
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002489057A
Other languages
English (en)
French (fr)
Inventor
Jamila Najib
Zouher Majd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genfit SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2489057A1 publication Critical patent/CA2489057A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Light Receiving Elements (AREA)
CA002489057A 2002-06-19 2003-06-19 Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100 Abandoned CA2489057A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR02/07542 2002-06-19
FR0207542A FR2841249A1 (fr) 2002-06-19 2002-06-19 Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100
PCT/FR2003/001888 WO2004000884A2 (fr) 2002-06-19 2003-06-19 Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100

Publications (1)

Publication Number Publication Date
CA2489057A1 true CA2489057A1 (fr) 2003-12-31

Family

ID=29719858

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002489057A Abandoned CA2489057A1 (fr) 2002-06-19 2003-06-19 Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100

Country Status (11)

Country Link
US (1) US20050152900A1 (enExample)
EP (1) EP1513878B1 (enExample)
JP (1) JP2006515561A (enExample)
AT (1) ATE356832T1 (enExample)
AU (1) AU2003267493A1 (enExample)
CA (1) CA2489057A1 (enExample)
DE (1) DE60312513T2 (enExample)
DK (1) DK1513878T3 (enExample)
ES (1) ES2283803T3 (enExample)
FR (1) FR2841249A1 (enExample)
WO (1) WO2004000884A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005093415A1 (ja) * 2004-03-29 2008-02-14 株式会社シバヤギ アポリポタンパク質ｂ−４８の測定方法およびその用途
WO2007058588A1 (en) * 2005-11-18 2007-05-24 T.A.C Thrombosis And Coagulation Aktiebolag Monoclonal antibodies against apolipoprotein m
JP2009531712A (ja) * 2006-03-23 2009-09-03 デ グスマン ブレイヤー、エメリタ アポリポタンパク質フィンガープリント技術
US8088593B2 (en) 2007-10-02 2012-01-03 Theranos, Inc. Modular point-of-care devices, systems, and uses thereof
JP5832723B2 (ja) * 2009-03-06 2015-12-16 協和メデックス株式会社 可溶性インターロイキン−２受容体定量用標準品
EP2408812B1 (en) * 2009-03-17 2015-12-16 CardioVax, LLC Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis and related proteins, peptides and compositions
WO2011060329A1 (en) 2009-11-14 2011-05-19 Kuang-Yuh Chyu Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis
US8506964B2 (en) 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
RU2013126628A (ru) 2010-11-12 2014-12-20 Седарс-Синаи Медикал Сентер Иммуномодулирующие способы и системы для лечения и/или предотвращения аневризм
CA2817543A1 (en) 2010-11-12 2012-06-07 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
CN106323875B (zh) 2011-01-21 2019-07-09 西拉诺斯知识产权有限责任公司 样品使用最大化的系统和方法
US20140170735A1 (en) 2011-09-25 2014-06-19 Elizabeth A. Holmes Systems and methods for multi-analysis
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US9268915B2 (en) 2011-09-25 2016-02-23 Theranos, Inc. Systems and methods for diagnosis or treatment
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
US9250229B2 (en) 2011-09-25 2016-02-02 Theranos, Inc. Systems and methods for multi-analysis
US11008628B1 (en) 2013-02-18 2021-05-18 Labrador Diagnostics Llc Systems and methods for analyte testing and laboratory oversight
US10401373B1 (en) 2013-02-18 2019-09-03 Theranos Ip Company, Llc Systems and methods for analyte testing and laboratory oversight
US10422806B1 (en) 2013-07-25 2019-09-24 Theranos Ip Company, Llc Methods for improving assays of biological samples
US11360107B1 (en) 2014-02-25 2022-06-14 Labrador Diagnostics Llc Systems and methods for sample handling
CN106053793A (zh) * 2016-06-20 2016-10-26 诺莱生物医学研究院（北京）有限公司 一种快速检测乳糜血的免疫层析试纸卡及其制备方法
WO2025111449A1 (en) * 2023-11-21 2025-05-30 Sun Diagnostics, Inc. Method and reagent to clear turbidity due to elevated triglycerides in a biological specimen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60193926A (ja) * 1984-03-15 1985-10-02 Tokyo Daigaku 単クローン性抗ヒトアポリポ蛋白質ｂ１００抗体
JPS617299A (ja) * 1984-06-20 1986-01-13 Dai Ichi Pure Chem Co Ltd ヒトアポリポ蛋白ｂ４８に高い特異性を有する単クローン性抗体
US6635623B1 (en) * 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors

Also Published As

Publication number Publication date
WO2004000884A2 (fr) 2003-12-31
DE60312513D1 (de) 2007-04-26
FR2841249A1 (fr) 2003-12-26
ES2283803T3 (es) 2007-11-01
ATE356832T1 (de) 2007-04-15
DK1513878T3 (da) 2007-07-16
AU2003267493A1 (en) 2004-01-06
US20050152900A1 (en) 2005-07-14
DE60312513T2 (de) 2007-12-06
EP1513878A2 (fr) 2005-03-16
EP1513878B1 (fr) 2007-03-14
JP2006515561A (ja) 2006-06-01
WO2004000884A3 (fr) 2004-04-08

Similar Documents

Publication Publication Date Title
EP1513878B1 (fr) Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100
EP0423301A1 (fr) Peptides synthetiques du conjugue de l'ubiquitine et de l'histone h2a.
WO1994004563A1 (fr) PEPTIDES CONTENANT DES SEQUENCES D'ACIDES AMINES RESPECTIVES SELECTIONNEES PARMI CELLES DE LA LIPOPROTEINE(a) ET DE L'APOLIPOPROTEINE(a), ANTICORPS RECONNAISSANT CES SEQUENCES D'ACIDES AMINES ET PROCEDE D'ANALYSE UTILISANT CES ANTICORPS
WO1990006371A1 (fr) ANTICORPS MONOCLONAUX ANTI-INTERLEUKINES 1α ET 1β, LEUR PROCEDE DE PRODUCTION ET APPLICATIONS DESDITS ANTICORPS A LA DETECTION DES INTERLEUKINES 1α et 1β ET EN THERAPEUTIQUE
EP1423707B1 (fr) Methodes de criblage de molecules utiles pour la prevention des maladies cardiovasculaires
EP2446038B1 (fr) Sequences, anticorps, procedes et necessaires pour la detection et le dosage in vitro de la periostine, en vue du diagnostic du suivi ou du pronostic de pathologies ou de phenomenes biologiques impliquant la periostine
EP0327418B1 (fr) Procédé immunométrique pour le dosage de particules de lipoprotéine, anticorps monoclonaux anti-Lp(a) et application au diagnostic de l'athérosclérose
JP3018110B2 (ja) モノクローナル抗体
FR2709492A1 (fr) Méthode d'immunodosage spécifique de la glutathion peroxydase plasmatique humaine, kit pour sa mise en Óoeuvre, oligopeptides et anticorps spécifiques de la méthode .
Nakamura et al. Significance of the variant and full-length forms of the very low density lipoprotein receptor in brain
EP1423708B1 (fr) Compositions et methodes pour le dosage de l'aa4rp
JP2005502029A (ja) アポｂおよび非アポｂ含有粒子中のアポｃｉｉｉを測定する新規な方法
KR0135708B1 (ko) 인간 혈중 아포지단백질 비-100(b-100)에 대한 신규 단일클론 항체 및 이들의 생산을 위한 재조합 하이브리도마 세포주
JPH0257177A (ja) モノクローナル抗体産生細胞ラインおよびモノクローナル抗体
JP2009263353A (ja) 抗ラットオステオカルシンモノクローナル抗体
FR2843395A1 (fr) Composition et methodes pour le dosage de l'aa4rp
JP2000279174A (ja) ヒトｌｄｌレセプターに対するモノクローナル抗体及びこれを用いる家族性高脂血症の判定方法
Najib Compositions and methods for apo-b48 and apo-b100 assay
JP2775445B2 (ja) 抗フェニトインモノクローナル抗体及びそれを産生するハイブリドーマ
JPH0257178A (ja) モノクローナル抗体産生細胞ラインおよびモノクローナル抗体
JP2010189381A (ja) 抗ヒトオステオカルシンモノクローナル抗体
FR2908413A1 (fr) Marqueur specifique d'une degradation oxydative de tissus contenant du collagene de type iii,moyens et methodes,kits de diagnostic de suivi ou de pronostic des pathologies ciblees par ce marqueur.
EP0252787A1 (fr) Polypeptides de surfaces cellulaires, isolés et purifiés, reconnus par les anticorps responsables de la pathogénie du lupus érythémateux disséminé (LED), leur méthode d'obtention et leur application au diagnostic du LED
JP2011190202A (ja) サポシンａ特異的抗体及びその作成方法
JPH06135997A (ja) イノシトール三リン酸受容体の精製法及び活性測定法

Legal Events

Date Code Title Description
FZDE Discontinued